Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC)

Luis E. Raez, Edgardo S. Santos, Gilberto Lopes, Manuel F. Rosado, Lawrence M. Negret, Caio Rocha-Lima, Kalhed Tolba, Nancy Farfan, Kara Hamilton-Nelson, Orlando Silva, Eloy Roman

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Background and aims: Platinum-based doublets are recommended as treatment for advanced or metastatic non-small-cell lung cancer (NSCLC); however, chemotherapy must be tailored to limit side effects. A phase II study was conducted to evaluate the efficacy and safety of oxaliplatin combined with docetaxel for NSCLC. Methods: Patients with stage IIIB or IV, chemotherapy-naive NSCLC received docetaxel 70 mg/m2, oxaliplatin 130 mg/m2, and pegfilgrastim 6 mg every 21 days for up to six cycles. Primary endpoint was overall response rate (ORR), secondary endpoints were progression-free (PFS) and overall survival (OS), and safety. Results: Twenty-nine patients were treated; 93% had stage IV disease and 28% had brain metastases. In 27 evaluable patients with follow-up, there were 10 partial responses for an ORR of 37% (90% confidence interval [CI], 22-55%). Median PFS was 4.6 months (95% CI, 2.6-6.5 months); 12-month PFS was 14.8% (95% CI, 3.4-34.0%). Median OS was 10.9 months (95% CI, 8.9-16.8 months); 12-month OS was 40% (95% CI, 19-61%) and 18-month OS was 16% (95% CI, 1-46%). In 29 treated patients, there were no unusual or unexpected adverse events. The most common grade 3 and 4 toxicities were anemia (14% of patients) and hyperglycemia (10%); there were only two reports of neutropenia; both were grade 1 or 2. Conclusion: These phase II findings suggest that the combination of oxaliplatin and docetaxel is active and well tolerated, and should be further investigated as a feasible treatment alternative for patients with advanced or metastatic NSCLC.

Original languageEnglish (US)
Pages (from-to)347-353
Number of pages7
JournalLung Cancer
Volume53
Issue number3
DOIs
StatePublished - Sep 1 2006

    Fingerprint

Keywords

  • Advanced disease
  • Chemotherapy
  • Docetaxel
  • First-line therapy
  • Non-small-cell lung cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology

Cite this

Raez, L. E., Santos, E. S., Lopes, G., Rosado, M. F., Negret, L. M., Rocha-Lima, C., Tolba, K., Farfan, N., Hamilton-Nelson, K., Silva, O., & Roman, E. (2006). Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer, 53(3), 347-353. https://doi.org/10.1016/j.lungcan.2006.05.023